Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2021 | Phase III VERONA study of venetoclax with azacitidine in treatment-naïve higher-risk MDS

Jacqueline Garcia • 9 Jun 2021
ASCO 2021
Myelodysplastic Syndromes Azacitidine Venetoclax
VERONA

Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the randomized, double-blind Phase III VERONA study (NCT04401748), a trial-in-progress evaluating venetoclax with azacitidine to assess the change in complate remission and overall survival in treatment-naive higher risk myelodsyplastic syndromes (MDS). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Jacqueline Garcia

Interpreting findings from the VERONA trial in MDS: factors influencing the lack of survival benefit 6:17
Interpreting findings from the VERONA trial in MDS: factors influencing the lack of survival benefit
Jacqueline Garcia • 7 Dec 2025
The current landscape of immunotherapy for AML: an update from ASH 2023 1:29
The current landscape of immunotherapy for AML: an update from ASH 2023
Jacqueline Garcia • 11 Dec 2023
The current landscape of treatment for HR-MDS: an update from ASH 2023 1:23
The current landscape of treatment for HR-MDS: an update from ASH 2023
Jacqueline Garcia • 11 Dec 2023
Venetoclax in combination with azacitidine for patients with treatment-naïve HR-MDS 5:52
Venetoclax in combination with azacitidine for patients with treatment-naïve HR-MDS
Jacqueline Garcia • 11 Dec 2023

Related Videos

Updated results from a Phase II trial of elritercept in LR-MDS 2:27
Updated results from a Phase II trial of elritercept in LR-MDS
Lynette Chee • 8 Dec 2025
Improving diagnostic procedures in MDS to avoid invasive bone marrow examination 3:53
Improving diagnostic procedures in MDS to avoid invasive bone marrow examination
Moshe Mittelman • 7 Dec 2025
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS 1:10
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS
Amer Zeidan • 5 Dec 2025
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial 1:11
Luspatercept initiated at the maximum-approved dose in transfusion-dependent LR-MDS: MAXILUS trial
Amer Zeidan • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals